Clinical Insights: September 27, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Likmez™ (metronidazole) Oral Suspension – New Drug Approval – September 25, 2023 – Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”) ”), a biopharmaceutical company focused on…
Clinical Insights: September 20, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ojjaara™(momelotinib) Tablets – New Drug Approval – September 15, 2023 – GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved Ojjaara™(momelotinib) for the…
Clinical Insights: September 13, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Aphexda™ (motixafortide) Lyophilized Powder for Injection – New Drug Approval – September 11, 2023 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company focused on certain cancers and rare…
Clinical Insights: September 6, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Reblozyl® (luspatercept-aamt) for Injection – New Expanded Label – August 28, 2023 – Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and…
Clinical Insights: August 30, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval No new update. New Drug Shortage August 28, 2023 Hyaluronidase Injection, Ovine (Discontinuation) August 25, 2023 Testosterone Gel (Discontinuation) August 24, 2023 Piroxicam…
Clinical Insights: August 23, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Veopoz™ (pozelimab-bbfg) Injection – New Drug Approval – August 18, 2023 – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food and Drug Administration (FDA) has approved Veopoz™ (pozelimab-bbfg)…
Clinical Insights: August 16, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Elrexfio™ (elranatamab-bcmm) Injection – New Drug Approval – August 14, 2023 – The Food and Drug Administration granted accelerated approval to elranatamab-bcmm (Elrexfio™, Pfizer, Inc.), a bispecific B-cell maturation antigen…
Clinical Insights: August 10, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Izervay™ (avacincaptad pegol) Intravitreal Solution – New Drug Approval – August 5, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), announced the U.S. Food…
Clinical Insights: August 2, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval RiVive™ (naloxone hydrochloride) Nasal Spray – New Drug Approval – July 28, 2023 – The U.S. Food and Drug Administration approved RiVive™, 3 milligram (mg) naloxone hydrochloride nasal spray for…
Clinical Insights: July 26, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Ycanth™ (cantharidin) Topical Solution – New Drug Approval – July 21, 2023 – FDA has approved Ycanth™ (cantharidin) for the topical (used on the skin) treatment of molluscum contagiosum…
Clinical Insights: July 19, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval Beyfortus™ (nirsevimab-alip) Injection – New Drug Approval – July 17, 2023 – The U.S. Food and Drug Administration approved Beyfortus™ (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV)…
Clinical Insights: July 12, 2023
Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy marketplace. Contact us to learn more. New Drug/Vaccine Approval No new update. New Indication/Dosage/Formulation Approval Leqembi®(lecanemab-irmb) Injection – New Expanded Label – July 12, 2023 – The U.S. Food and Drug Administration converted Leqembi®(lecanemab-irmb), indicated to treat adult…